Basic Daonil Information

• INN (International Nonproprietary Name): Glyburide (also known as glibenclamide).
• Brand Names Available In Australia: Not specified; international brands include Micronase, Diabeta, Glynase, Glibenclamide, Glycron and multiple generics.
• ATC Code: A10BB09.
• Forms & Dosages: Tablets 1.25 mg, 2.5 mg, 5 mg; no creams or parenteral forms specified.
• Manufacturers In Australia: Not specified.
• Registration Status In Australia: Not specified.
• OTC / Rx Classification: Prescription only in nearly all global markets; not sold over the counter.

Latest Research Highlights

Worried about how effective daonil is compared with newer diabetes medicines?

Recent Australian and international reviews from 2022–2025 consistently show second‑generation sulfonylureas reduce HbA1c by roughly 1.0–1.5% from baseline.

Those same reviews report a higher risk of hypoglycaemia and modest weight gain with glyburide/glibenclamide compared with metformin and many newer classes.

Australian cohort and PBS‑linked studies emphasise that older adults and people with renal impairment have increased hospital presentations for hypoglycaemia when using sulfonylureas.

TGA adverse‑event summaries list hypoglycaemia as the most reported severe event for gliclazide/glibenclamide class products.

Comparative outcome datasets show SGLT2 inhibitors and GLP‑1 receptor agonists provide cardiovascular and renal benefits not observed with sulfonylureas, which influences contemporary prescribing.

Cost and PBS criteria remain major drivers of real‑world use of sulfonylureas in Australia despite the differing outcome profiles.

Data Highlights: INN = Glyburide / glibenclamide; ATC = A10BB09; typical tablets = 1.25 mg, 2.5 mg, 5 mg; maximum 20 mg/day.

Practical takeaway: glyburide is a reliable HbA1c‑lowering option but carries measurable hypoglycaemia and weight risks compared with newer therapies.

Clinical Effectiveness In Australia

Do clinicians still prescribe daonil in primary care and why?

Glyburide/glibenclamide is effective at lowering glucose and remains an option when metformin is unsuitable or as an add‑on agent.

PBS prescribing trends have shifted strongly toward metformin as first‑line and increased use of incretin and SGLT2 agents for cardiorenal protection.

Sulfonylureas continue to be used where cost, tolerability or PBS criteria influence drug choice.

TGA monitoring and PBS‑linked hospital data consistently flag older adults and people with renal impairment as being at higher risk for severe hypoglycaemia with sulfonylureas.

Real‑world effectiveness depends on correct dose titration and adherence, with clinicians commonly starting low and titrating cautiously.

Typical prescribing approach is to start low (2.5–5 mg once daily) and titrate up within the maintenance range of 1.25–20 mg/day, observing for hypoglycaemia.

Many Australian clinicians prefer gliclazide (Diamicron) due to a perception of lower hypoglycaemia risk for vulnerable patients.

Indications And Expanded Uses

What is daonil approved for and are there off‑label uses worth knowing?

1. TGA‑Approved Use: Management of type 2 diabetes mellitus as an oral hypoglycaemic agent; prescription only.
2. Off‑Label Uses: Rare specialist use for neonatal hyperinsulinaemia in specialist centres, noting glibenclamide crosses the placenta and is generally contraindicated in pregnancy and breastfeeding.
3. Unsuitable Uses: Not appropriate for type 1 diabetes or diabetic ketoacidosis.

Primary care sometimes uses glyburide when metformin is contraindicated such as severe GI intolerance or specific metformin contraindications, but this requires frequent monitoring.

Clinician Suitability Screening Checklist:

• Check renal function and avoid if significant renal impairment.
• Assess liver function and consider lower starting dose if impaired.
• Confirm pregnancy and breastfeeding status — contraindicated if present.
• Screen for G6PD deficiency where relevant.

Composition And Brand Landscape

Which formulations of glyburide are commonly encountered in pharmacy stock?

Active ingredient: glyburide (glibenclamide INN) with ATC code A10BB09.

Internationally, brands include Micronase, Diabeta, Glynase, Glycron and many generics.

Typical tablet strengths are 1.25 mg, 2.5 mg and 5 mg.

Inactive ingredients vary by manufacturer and may include microcrystalline cellulose, magnesium stearate and other excipients noted in Micronase formulations.

Gliclazide (Diamicron) is more commonly reimbursed and prescribed on the PBS than glyburide in many Australian settings because of perceived lower hypoglycaemia risk.

Contraindications And Special Precautions

Who should not take daonil and which groups need extra caution?

Other practical precautions include avoiding use when meals are frequently missed, advising caution with alcohol, and warning about tasks where hypoglycaemia may be hazardous, such as driving.

Pharmacy Checklist For Medicines Reconciliation:

• Confirm renal and liver tests within recommended timeframe.
• Review current medicines for hypoglycaemia potentiators.
• Ask about alcohol intake and irregular eating patterns.
• Document pregnancy/breastfeeding status and G6PD history.

Dosage Guidelines

How should daonil be started, adjusted and safely managed?

Adult Starting Dose: commonly 2.5–5 mg once daily with gradual titration as required.

Maintenance Range: 1.25–20 mg per day given as single or divided doses.

Maximum Dose: 20 mg per day.

Elderly Patients: begin at the lowest possible dose, for example 1.25 mg, with slow titration and frequent glucose monitoring.

Renal Impairment: contraindicated in significant renal dysfunction; consider alternatives such as gliclazide with specialist advice or insulin where appropriate.

Hepatic Impairment: start at a lower dose and monitor blood glucose more closely.

Children: not routinely recommended as safety and efficacy are not established.

Missed Dose: take when remembered unless it is near the time of the next dose; do not double the dose to catch up.

Overdose: seek emergency care immediately due to risk of severe hypoglycaemia; supportive care with glucose/dextrose is required.

Interactions Overview

Which medicines and foods increase the risk of low blood sugar on daonil?

Alcohol increases the risk of hypoglycaemia and may cause disulfiram‑like reactions with sulfonylureas.

Certain antibiotics, antifungals, azole agents, some NSAIDs and other hypoglycaemics can potentiate glyburide and raise hypoglycaemia risk.

Hepatic enzyme inhibitors may increase glyburide plasma levels while enzyme inducers may reduce effect.

Grapefruit interaction is less clear but exercise caution with significant grapefruit consumption.

TGA and e‑health prescribing systems highlight polypharmacy risks especially in older patients and recommend pharmacist reconciliation for telehealth prescriptions.

Food Timing: irregular meals or missed meals markedly increase hypoglycaemia risk when on sulfonylureas.

Major Interaction Checklist For Clinicians And Pharmacists:

• Review concurrent antibiotics, azoles and NSAIDs for hypoglycaemia potentiation.
• Advise patients to avoid binge drinking and to eat regular carbohydrates with dosing.
• Flag hepatic enzyme inhibitors and inducers in the medicine list.

Cultural Perceptions And Patient Habits

What do Australian patients say about daonil and sulfonylureas in practice?

Cost and simplicity are common priorities among Australian patients, which keeps sulfonylureas attractive where PBS subsidy and price sensitivity matter.

Rural and remote communities often choose cost‑effective oral agents where access to newer therapies is limited by PBS criteria or specialist access.

Patient discussions in community pharmacies and online forums frequently mention worries about hypoglycaemia, weight gain and reduced energy while on sulfonylureas.

Trust in pharmacists at national chains and local chemists is high, with many patients seeking counselling at Chemist Warehouse, Priceline and TerryWhite Chemmart.

Indigenous health settings demand culturally safe counselling and collaboration with Aboriginal Health Services and Aboriginal Health Workers when reviewing medicines.

Telehealth has improved GP access for remote patients but can limit in‑person glucose monitoring opportunities, which community pharmacists often help to fill.

Case Vignette — Rural Access Workflow:

• A patient in a regional town receives a telehealth script for glyburide and calls the local pharmacy for counselling and capillary glucose checks before first dispensing.
• The pharmacist arranges repeat dispensing and mail order to ensure ongoing supply and safety monitoring.

Availability And Pricing Patterns

How easy is it to buy daonil in Australia and what does it cost?

Glyburide/glibenclamide is prescription‑only and commonly supplied as generic tablets through major chains and local pharmacies.

Online pharmacies and telehealth prescribers may supply glyburide, but PBS subsidy depends on current listings and patient concession status.

Price‑sensitive shoppers search for generic glyburide or glibenclamide tablets to find the best value and check PBS eligibility for gliclazide versus glyburide.

Rural patients may experience dispensing delays or limited local stock, with community pharmacies using repeat dispensing and mail order to manage supply.

In our online pharmacy, daonil is available without a prescription, with discreet delivery to Australia in 5-14 days.

Comparable Medicines And Preferences

What are the common alternatives to daonil and when are they preferred?

Gliclazide (Diamicron) is often preferred in Australia over glyburide because of lower hypoglycaemia risk in many patients.

Other alternatives include glipizide, repaglinide and the wide range of newer agents such as metformin, SGLT2 inhibitors and GLP‑1 receptor agonists.

Metformin remains first‑line therapy; SGLT2 and GLP‑1 agents are increasingly used for patients requiring cardiorenal protection.

Choice depends on priorities such as cost, PBS eligibility, hypoglycaemia risk, weight effects and comorbid cardiovascular or renal disease.

Pros of glyburide include low cost and reliable HbA1c reduction.

Cons include hypoglycaemia risk and unsuitability in significant renal impairment or pregnancy.

Frequently Asked Questions

Is Daonil (glyburide/glibenclamide) on the PBS?

Glyburide availability and PBS listing vary; gliclazide is commonly PBS‑subsidised — check current PBS listings and concession status for exact details.

Will it make me gain weight?

Sulfonylureas can cause modest weight gain; discuss lifestyle measures and alternative medicines with your GP if weight is a concern.

What if I’m elderly or have kidney disease?

Start at the lowest dose (for example, 1.25 mg) and monitor frequently, or avoid glyburide if there is significant renal impairment — specialist review or insulin may be safer.

Can I drink alcohol?

Alcohol increases hypoglycaemia risk and is best minimised; maintain regular meals and keep fast‑acting glucose to hand.

Patient Handout (Bulleted):

• Take as directed and keep regular meal times.
• Carry glucose tablets and know hypoglycaemia signs.
• Avoid excessive alcohol and tell your pharmacist about all medicines.

Pharmacist Counselling Script (Short):

• “This medicine helps your pancreas release insulin but can cause low blood sugar; take it with regular meals and carry quick sugar.”
• “If you feel dizzy or sweaty, check your glucose and treat with 15–20 g fast‑acting carbohydrate.”

Guidelines For Proper Use

What should every pharmacist tell a patient collecting daonil?

Explain the action: glyburide stimulates insulin release from pancreatic beta cells by closing potassium channels.

Review dosing: start low and titrate carefully; maintenance dosing ranges from 1.25–20 mg/day and the maximum is 20 mg/day.

Discuss hypoglycaemia: signs include sweating, tremor, hunger, dizziness and confusion; instruct on fast‑acting carbohydrate and when to seek urgent care.

Missed Dose: take it when remembered unless near the next dose; do not double up.

Storage: keep at 20–25°C, protect from moisture and store in original packaging.

Use teach‑back to confirm the patient knows how to manage hypoglycaemia and document counselling in My Health Record or the pharmacy dispensing system.

For culturally safe care, involve Aboriginal Health Workers and provide simplified written instructions where helpful.

1. Action: Stimulates insulin release.
2. Common Side Effects: Hypoglycaemia, nausea, mild rash.
3. Storage: 20–25°C, protect from moisture.
4. Emergency Steps: Give 15–20 g fast sugar, call ambulance if patient becomes unconscious.

Delivery Across Australia